Mastodawn

elucid Nov 13, 2022

Dr. Lesh is currently CEO and founder of Syntegra, a company focused on privacy-preserved synthetic data that bridges the gap between an organization’s data privacy and data science needs.
Visit: https://bit.ly/3AbMbXl

Elucid Appoints Dr. Michael Lesh to Board of Directors - Elucid

Elucid, Inc., a leading medical technology company providing physicians with AI-powered imaging analysis software to characterize cardiovascular disease, today announced the addition of Michael D. Lesh, MD, FACC, to its Board of Directors.

Elucid

elucid Aug 14, 2022

Elucid Software Quantifies Plaque Morphology to Enable Better Assessment of IPE Treatment Effects!
Read more click here: https://bit.ly/3K0VRYf

Plaque Morphology to Enable Better Assessment of IPE Treatment Effects

Elucid Presents Results of the EVAPORATE Study at ESC Preventive Cardiology 2021 Late Breakers. Elucid Software Quantifies Plaque Morphology to Enable Better Assessment of IPE Treatment Effects

Elucid

elucid Apr 19, 2022

#Elucid is a Boston-based medical technology company using uniquely interpretable and validated AI to provide physicians with a cost-effective means to optimize #treatment decisions for patients with known or suspected cardiovascular disease.
Visit: https://bit.ly/3xC8yVf

Elucid Eyes Big Opportunity to Save Lives with Software Amidst Major Guideline Changes - Elucid Vivo

ACC/AHA Endorse Cardiovascular Computed Tomography Angiography (CCTA) in New Chest Pain Guidelines BOSTON–(BUSINESS WIRE)–Elucid, a medical technology company developing AI software to enable cardiovascular disease detection, expects newly issued guidelines will be a catalyst for non-invasive image, revolutionizing the way patients with coronary artery disease are diagnosed and treated. In a highly anticipated document published […]

Elucid Vivo